Draft:Bamlanivimab

 AbCellera-Discovered Antibody Receives U.S. FDA Emergency Use Authorization as a Monotherapy for the Treatment of COVID-19

Retrieved on: 
Tuesday, November 10, 2020
Research, Infectious diseases, FDA, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Medical specialties, Medicine, Clinical medicine, Immunology, Draft:Bamlanivimab, Immune system, Glycoproteins, Antibodies, Biotechnology, Neutralizing antibody, Coronavirus disease, Monoclonal antibody, bamlanivimab, BLAZE-1, AbCellera Biologics Inc.

We commend the Lilly team for their tireless efforts to combat COVID-19 and for starting antibody manufacturing at risk in advance of clinical results.

Key Points: 
  • We commend the Lilly team for their tireless efforts to combat COVID-19 and for starting antibody manufacturing at risk in advance of clinical results.
  • Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2.
  • It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19.
  • Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.

GenScript Receives FDA Emergency Use Authorization for World's First SARS-CoV-2 Neutralizing Antibody Detection Kit

Retrieved on: 
Monday, November 9, 2020
Medical specialties, Medicine, Branches of biology, Antibodies, Neutralizing antibody, Coronavirus disease, Emergency Use Authorization, Draft:Bamlanivimab, COVID-19 testing

PISCATAWAY, N.J., Nov. 9, 2020 /PRNewswire/ --GenScript USA Inc., the world's leading research reagent provider,announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the cPass SARS-CoV-2 Neutralization Antibody Detection Kit.

Key Points: 
  • PISCATAWAY, N.J., Nov. 9, 2020 /PRNewswire/ --GenScript USA Inc., the world's leading research reagent provider,announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the cPass SARS-CoV-2 Neutralization Antibody Detection Kit.
  • This is the first commercially available test to specifically detect neutralizing antibodies without the use of live virus.
  • The test measures the presence of neutralizing antibodies in any sample, from those from patients recovering from COVID-19 or those vaccinated against SARS-CoV-2.
  • The conventional method for measuring neutralizing antibodies requires testing to be performed in a high safety-level facility (BSL3) staffed with specialized personnel.